Mild Cognitive Impairment in Parkinson's Disease

Completed · Phase 4 · Has a placebo group

Conditions studied: Parkinson's Disease, Mild Cognitive Impairment

In brief

Mild cognitive impairment, including difficulty with solving problems, planning, attention, or recalling information, can be a significant problem for individuals with Parkinson's disease. Even mild cognitive difficulties can lead to worse functioning, quality of life, depression, and difficulty for caregivers. Thus, ideally treatment at this stage would improve both cognitive symptoms and some of the other problems associated with these symptoms. Despite the fact that mild cognitive impairment is a serious problem for Parkinson's disease patients little is known about how best to treat it. This study is a 24-week clinical trial to see if a Food and Drug Administration (FDA)-approved drug, the Exelon (rivastigmine) Patch, is useful in treating mild cognitive impairment in patients with Parkinson's disease. Currently, the Exelon (rivastigmine) Patch is FDA-approved for the treatment of mild to moderate dementia in Alzheimer and Parkinson's disease patients.

Key facts

Study ID

NCT01519271

Run by

University of Pennsylvania

People needed

28

Starts

2011-12-01

Expected to finish

2014-06-01

Last updated by the study team

2017-04-07

Who can join

Age: 40 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must be experiencing symptoms of mild cognitive impairment; this will be determined by study personnel.
• Participants must be on a sable medication regimen for 2 months prior to starting the study (necessary dose adjustments during the study are acceptable).
• Participants are capable of giving informed consent supported by not meeting Parkinson's disease Dementia criteria; this will be determined by study personnel.

You may not qualify if…

• Active suicide ideation.
• Weighing less than 100 lbs (45 kgs).
• History of Deep Brain Stimulation surgery.
• Diagnosis of Dementia
• Taking certain types of medications may be an exclusion criteria, this will be reviewed with all potential participants.
• Females that are pregnant, planning to become pregnant, or are breastfeeding will not be included in the study. Females of childbearing potential will need to verify that they are not pregnant by a negative urine pregnancy test.

Where it is running

• University of Pennsylvania, Ralston House — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.